Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
March 03 2017 - 4:21PM
Edgar (US Regulatory)
Tokai Pharmaceuticals, Inc.
255 State Street, 6
th
Floor
Boston, MA 02109
March 3, 2017
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Notice of disclosure filed in
Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
To Whom it May Concern:
Pursuant to Section 219 of the
Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Tokai Pharmaceuticals, Inc. has made disclosure pursuant to those provisions in its
Annual Report on Form
10-K
for the fiscal year ended December 31, 2016, which was filed with the Securities and Exchange Commission on March 3, 2017.
|
|
|
Respectfully submitted,
|
|
TOKAI PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Jodie P. Morrison
|
Name:
|
|
Jodie P. Morrison
|
Title:
|
|
President and Chief Executive Officer
|
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart
From Sep 2023 to Sep 2024